|
gptkbp:instanceOf
|
drug
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Avandia
|
|
gptkbp:chemicalFormula
|
C18H19N3O3S
|
|
gptkbp:clinicalTrials
|
gptkb:Rosiglitazone_Evaluated_for_Cardiac_Outcomes_and_Regulation_of_Glycemia_in_Diabetes_(RECORD)
RECORD trial
ADOPT trial
Rosiglitazone in Type 2 Diabetes (ADOPT)
|
|
gptkbp:contraindication
|
liver disease
heart disease
|
|
gptkbp:dosageForm
|
15 mg
8 mg
30 mg
|
|
gptkbp:drugInterdiction
|
thiazolidinedione
|
|
gptkbp:endOfLife
|
3 to 4 hours
|
|
gptkbp:firstAppearance
|
1999
|
|
gptkbp:formulation
|
oral tablet
|
|
gptkbp:gestationPeriod
|
C
|
|
gptkbp:hasAwards
|
not recommended
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rosiglitazone
|
|
gptkbp:interactsWith
|
insulin
other antidiabetic agents
CYP2C8 inhibitors
CYP2C8 inducers
|
|
gptkbp:market
|
2010
|
|
gptkbp:marketedAs
|
gptkb:GlaxoSmithKline
|
|
gptkbp:numberOfTeams
|
122320-73-4
|
|
gptkbp:nutritionalValue
|
liver
|
|
gptkbp:offersCoursesIn
|
A10BG01
|
|
gptkbp:regulatoryCompliance
|
restricted use
|
|
gptkbp:releaseYear
|
1996
|
|
gptkbp:safetyFeatures
|
increased risk of stroke
increased risk of myocardial infarction
monitor liver function
monitor heart failure
monitor weight gain
|
|
gptkbp:sideEffect
|
heart failure
weight gain
hypoglycemia
edema
|
|
gptkbp:triggerType
|
PPAR-gamma agonist
|
|
gptkbp:usedFor
|
type 2 diabetes
|
|
gptkbp:waterManagement
|
urine
|